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Abstract: High grade serous ovarian cancer (HGSC), the most lethal and frequent type of 
epithelial ovarian cancer (EOC), has poor long term prognosis due to a combination of 
factors: late detection, great metastatic potential and the capacity to develop resistance to 
available therapeutic drugs. Furthermore, there has been considerable controversy 
concerning the etiology of this malignancy. New studies, both clinical and molecular, 
strongly suggest that HGSC originates not from the surface of the ovary, but from the 
epithelial layer of the neighboring fallopian tube fimbriae. In this paper we summarize data 
supporting the central role of fallopian tube epithelium in the development of HGSC. 
Specifically, we address cellular pathways and regulatory mechanisms which are 
modulated in the process of transformation, but also genetic changes which accumulate 
during disease progression. Similarities between fallopian tube mucosa and the malignant 
tissue of HGSC warrant a closer analysis of homeostatic mechanisms in healthy epithelium 
in order to elucidate key steps in disease development. Finally, we highlight the importance 
of the cancer stem cell (CSC) identification and understanding of its niche regulation for 
improvement of therapeutic strategies. 
Keywords: serous ovarian cancer; fallopian tube; p53 signature; STIC; cellular 
transformation; cancer stem cells (CSC); tumor microenvironment  
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1. Introduction  
Epithelial ovarian cancer (EOC) represents a very heterogeneous disease with widely varying 
histology, pathogenesis and clinical presentation, resulting in greatly different outcomes. It is the 
fourth leading cause of cancer deaths among women in industrialized countries. According to the 
classification of the International Federation of Gynecology and Obstetrics (FDA, USA) in more than 
75% of patients, initial diagnosis is made at stage III or IV of the disease. Consequently, despite 
advances in surgery and therapy, overall prognosis remains relatively poor, with a 10 year relative 
survival rate of less than 35% [1,2]. Chemotherapy resistance mechanisms, pre-existing resistant 
clones at initial presentation that survive suboptimal surgery, and unknown, molecular fingerprints 
inducing and maintaining invasion and metastasis are some of the underlying mechanisms responsible 
for this unfavorable prognosis. 
Recent pathological and genomic findings strongly suggest that many ovarian cancers are derived 
from non-ovarian tissues. The different histotypes share few molecular similarities and present with such 
different pathology that pelvic or peritoneal cancer may be a more suitable definition of the disease. For 
example, the distal fallopian tube has been identified as a source of high-grade serous ovarian cancers, 
the deadliest and most prevalent form [3]. The other histological subtypes of ovarian cancer consist of 
clear cell and endometrioid cancer, as well as mucinous ovarian cancer, which are proposed to have 
origins in the uterine and gastrointestinal tract, respectively (Figure 1A). In comparison to serous ovarian 
cancer, other histological subtypes present a distinct molecular and genetic profile (Figure 1B). This is in 
congruence with clear differences in morphology. For example, clear cell carcinoma was found to have a 
high incidence of PI3 kinase mutations and ARID1A [4,5], endometrioid tumors are characterized by 
high proportions of β-catenin mutations [6] and mucinous cancers predominantly show mutations in the 
Ras pathway [7]. However, for all subtypes, the precise mechanisms of the initial molecular 
transformation and spread of malignant cells to the ovary remain obscure. 
Serous ovarian cancers vary in differentiation status, cytological features and genetic fingerprint, 
and are classified as Type I and Type II cancers: Low Grade Serous Carcinoma (LGSC) (Type I) and 
High Grade Serous Carcinoma (HGSC) (Type II). LGSCs exhibit a gradual, slow transition from 
benign to malignant state, involving multiple somatic mutations in K-Ras, BRAF, and PPP2R1A [8], 
thereby altering multiple cell growth and cell division related signaling pathways, which lead to a 
stepwise transformation and development of malignancy. HGSC on the other hand, are genetically 
diverse, fast-growing and -disseminating aggressive tumors, which bear only a small number of core 
somatic mutations resulting in a de novo, diffusely disseminated peritoneal disease. Tumor suppressor 
p53 inactivation is detected in more than 95% of cases and there is frequent inactivation of the 
BRCA1/2 DNA damage repair pathway within an otherwise greatly heterogeneous genetic background 
of sporadic HGSC patients. Around 10% of total HGSC cases are diagnosed in women with hereditary 
BRCA1/BRCA2 germ line mutations [9], while the remaining 90% are sporadic. 
Despite increasing efforts in terms of more radical surgery and more efficient systemic treatment, 
survival of women with epithelial ovarian cancer has changed little since platinum-based treatment 
was introduced over 30 years ago. Therefore, understanding the biological origins and early stages of 
the disease remains imperative. Greater efforts should be made in the area of disease prevention, 
especially in BRCA mutation carriers. In this respect, it is necessary to elucidate the role of the 
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fallopian tube as the putative tissue of origin of ovarian cancer. Increasing evidence suggests that the 
role of the ovary in the carcinogenesis process is limited to creating an unfavorable microenvironment, 
by releasing toxic substances into the follicular fluid after ovulation, that create local inflammatory 
processes which affect the epithelium of fallopian tube fimbriae, leading to neoplastic changes and 
finally malignant transformation [10]. Thus, understanding the regulatory mechanisms and signaling 
pathways in fallopian tube epithelium is becoming a focal point of serous ovarian cancer research. In 
this paper we provide an overview of the current findings about the genetic makeup and cellular 
phenotype of ovarian cancer tissue, and focus on the importance of the fallopian tube in its etiology. 
Figure 1. Epithelial ovarian cancer is heterogeneous in origin and molecular 
characteristics. (A) Serous ovarian cancer, the most prevalent type of epithelial ovarian 
cancer (EOC), originates in the fallopian tube, while other histological types are presumed 
to originate from the uterus and gastrointestinal tract; (B) The diversity of frequent somatic 
mutations in different types of EOC reflects the great divergence in histopathology and 
clinical presentation [5,8,11]. 
 
2. Fallopian Tube as Extra-Ovarian Tissue of Origin of Serous Ovarian Cancer 
No ovarian precursor lesions of HGSC have been identified so far, which should theoretically be 
the case if ovarian cancer originated exclusively from the ovarian surface. Instead, multiple lines of 
evidence point to the fallopian tube as the tissue of origin. During embryonic development, the 
primordial structure known as the Müllerian duct gives rise to the proximal two thirds of the vagina, 
the cervix, uterus and fallopian tubes, whereas the ovaries originate from the mesoderm which also 
forms the urinary tract (Figure 2A). This is reflected in profound differences in the cellular phenotype 
and characteristics of the finally developed epithelial tissues of the adult. In this context, the fact that 
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whole genome expression profiling of HGSC samples showed a significant correlation with the 
expression patterns of normal fallopian tube epithelium provides important clues about its  
putative origin [12]. 
Figure 2. High grade serous ovarian cancer (HGSC) originates from fallopian tube 
mucosa. (A) The two models of ovarian cancer origin, comparing the old metaplasia model 
of OSE and the model with fallopian tube fimbriae as the source of malignant cells. 
Different colors, (blue = ovary; and orange = fallopian tube) depict the different embryonic 
origin of the tissues as well as differences in cellular phenotype. Notably, malignant cells 
of HGSC also have a Müllerian phenotype (orange); (B) An ovarian origin of serous 
ovarian cancer would require a 3-step process (middle row), involving first the conversion 
of simple cuboidal into more complex columnar epithelium, followed by de-differentiation 
during tumor development, whereas the fallopian tube model proposes a direct, one-step 
malignant transformation of fallopian tube secretory cells; (C) Stepwise development of 
STICS in the fallopian tube epithelium involves p53 inactivation, followed by additional 
genomic changes (e.g., BRCA mutations).  
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Further molecular evidence was provided by screening of serous ovarian cancer cell lines, which 
examined the significance of individual genes for the survival and proliferation of cancerous cells by 
RNAi-loss-of-function analysis. A genome-wide screen of pooled shRNAs in 25 ovarian cancer cell 
lines identified the transcription factor PAX8 (paired box gene 8), which is amplified in primary high 
grade ovarian tumors, as essential for survival and proliferation [13]. Pax8 belongs to the family of 
homeobox transcription factors, proteins which are uniquely positioned upstream in the cascade of 
molecular events which determine commitment of cells towards a particular developmental route. It is 
essential for the development of the lower genital tract and also plays a role in the early cell fate 
determination of the thyroid gland and kidney [14]. In the adult, the secretory cells of the fallopian 
tube epithelial monolayer express high levels of PAX8, but neighboring ciliated cells do not, and 
neither do any cells on the surface of healthy ovaries [15].  
Data from other malignancies indicate the existence of a common mechanism of carcinogenesis 
whereby transcription programs controlled by “master regulator” genes that are transiently active 
during early development, are incorporated into the survival repertoire of malignant cells (e.g., MITF 
for melanoma and SOX2 for colon). Therefore it is tempting to postulate that the requirement for 
PAX8 for the survival and proliferation of ovarian cancer cell lines represents exactly such a 
regulatory mechanism. The absence of PAX8 in the adult ovary also strengthens the argument that 
HGSC originates in the fallopian tube mucosa, from where it spreads to the ovary. Otherwise, 
epithelial ovarian surface cells would have to undergo metaplastic transformation, and start expressing 
PAX8 and other downstream targets prior to malignant transformation.  
A tubal origin of ovarian carcinoma is also supported by several histological and pathological 
observations. The normal ovarian surface epithelium (OSE) is a simple monolayer of squamous to 
cuboidal epithelium which expresses no specific markers of tissue differentiation (Figure 2B). It has 
only rudimentary tight junctions and cell-to-cell adhesion is regulated mainly by desmosomes, thus it 
is attached to the underlying basal lamina only loosely. Compared to other mucosal epithelia it 
expresses very low levels of E cadherin, and there is no expression of CA125 which is abundant in the 
surrounding extra-ovarian mesothelium, the epithelial layer which covers the abdominal cavity and 
reproductive organs [16,17]. In comparison, the fallopian tube epithelium is a monolayer of fully 
differentiated columnar, secretory and ciliated epithelial cells, which are interconnected by complete 
adhesion junction belts, the zonula adherens, and express high levels of E cadherin. Thus, a model by 
which ovarian cancer arises from OSE assumes the existence of transformation mechanisms which 
trigger the transition from simple cuboidal epithelium into more complex, tightly organized and more 
differentiated epithelium with many features of fallopian tube mucosa, which is contradictory to the 
accepted paradigm of malignant transformation.  
Low grade serous cancer is frequently confined to the ovary without spread in the peritoneal cavity 
and more often diagnosed in earlier stages, and thus, until recently, widely accepted to develop from 
ovarian cortical cysts which undergo Müllerian metaplasia. In the process of stepwise transformation, 
these genetically stable cancers presumably arise from cysts converted to benign cyst adenomas and 
then to borderline tumors. Nevertheless, a detailed histological study of 178 patient samples of adnexal 
serous tumors, cyst adenomas, borderline tumors, and control samples of non-neoplastic ovarian tissue 
provided compelling evidence that ovarian cortical cysts also originate from fallopian tube fimbrial 
cells that have formed inclusion cysts, as no histological proof could be found in support of the 
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Müllerian metaplasia hypothesis [18]. Two types of inclusion cysts were detected in the ovary: 22% 
were of ovarian epithelial origin, confirmed by calretinin staining, while 78% contained  
PAX8-positive secretory cells as well as ciliated cells, confirmed by tubulin staining, similar to normal 
tubal epithelium. Importantly, no cysts were found to contain a mixture of cell types which would be 
expected if metaplasia was a result of random conversion of ovarian surface epithelial cells. Instead, 
the presence of ciliated cells typical of fallopian epithelium in cortical cysts followed by gradual 
reduction in their frequency during the steps of malignant transformation speaks in favor of a model 
whereby the physiological tubal mucosa migrates to the ovary cortex, perhaps during the wound 
healing process following follicle rupture, and becomes encapsulated, forming an inclusion cyst. 
During malignant transformation, gradual expansion of secretory cells then occurs at the expense of 
ciliated cells in a step wise reduction of tubulin-positive cells from the epithelial inculsion cyst (30%) 
via serous cystadenoma (10%) and borderline tumor (5%) to complete absence in low grade serous 
cancer. As no cilia are found in malignant tissues of either histological types of serous ovarian cancer 
(LGSC and HGSC), it is difficult to reconcile how conversion of OSE cells into fallopian tube cells 
would first lead to the creation of both ciliated and secretory cells only for the former ones to be lost at 
later stages of the process (Figure 2B).  
3. Serous Tubal Intraepithelial Carcinoma (STIC) in Asymptomatic BRCA Mutation Carriers 
and Sporadic HGSC Cases 
BRCA1 and BRCA2 germline mutations are responsible for the vast majority of cases of hereditary 
ovarian cancer, which represents approximately 10% of all cases. The lifetime risk of developing 
ovarian cancer is estimated to be 54% and 23% for carriers of BRCA1 and BRCA2 mutations, 
respectively (King et al., 2003). However, BRCA inactivation is also frequently identified in sporadic 
cases of HGSC, as reported by the Cancer Genome Atlas Research Network [19], resulting in the term 
“BRCAness”, to describe the genetic profile of sporadic cases that resemble the profile of cancers from 
germline mutation carriers. In addition to BRCA1 and BRCA2 germline mutations, the BRCA1 
promoter was found to be hypermethylated and therefore epigenetically silenced in 56 of 489 sporadic 
cases (11.5%). Despite the severe hereditary burden for BRCA1/BRCA2 mutation carriers to develop 
ovarian cancer, histological examination of tissue from prophylactic salpingo-oophorectomy failed to 
find any notable differences in the incidence of premalignant lesions of the ovarian epithelium compared 
to controls. On the contrary, the procedure revealed the existence of in situ malignant tumors (serous 
tubal intraepithelial carcinomas, STICs) in the fallopian tube mucosa in up to 10% of cases. This finding, 
independently confirmed in numerous prospective studies from different clinical centers [20–25], 
presents striking in vivo evidence that early “ovarian cancer” resides in the fallopian tube prior to 
migration to the neighboring ovary or peritoneum. STICs have recently been confirmed as putative 
precursors of HGSCs based on findings demonstrating identical TP53 mutations indicative of a clonal 
relationship between the two malignancies [26]. Also, STICs express several potential oncogenes 
frequently found in HGSC, further linking both lesions [18].  
In sporadic cases of HGSC, analysis of malignant samples after surgery for advanced stage ovarian 
cancer revealed the existence of STICs within the fallopian tube in 67% of cases, 92% of which were 
confined to the fimbriated end [27]. These findings were confirmed by Kindelberger [28]. Other 
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studies revealed a significant involvement of the fallopian tube in primary peritoneal serous carcinoma 
as well, with 47% of completely inspected tubes containing STICs [29]. The presence of STICs in 
fallopian tubes of patients with ovarian and peritoneal cancers could possibly explain the causative 
factor of primary cancers of the peritoneum, in the same way as fimbrial epithelium gives rise to high 
grade serous cancers of the ovary. 
However, the discovery of STICs, although important, does not resolve the question of HGSC 
etiology, as it already represents an early malignant stage of the disease. Furthermore, some important 
distinctions between STIC and HSGC remain to be addressed in order to establish a causal 
relationship. Since STICs are non-invasive carcinomas, further genetic changes and/or alterations in 
cellular phenotype must occur prior to the transition to clinically recognizable HGSC. Due to the lack 
of substantial histological data sets of fallopian tube mucosa from healthy women without a hereditary 
predisposition to HGSC, it remains unclear if STICs always precede HGSC. Also, although pathology 
studies confirmed extensive tubal involvement in sporadic and hereditary HGSC cases, the clinical 
picture is not uniform, as there is still a proportion of ovarian and peritoneal cancers without detectable 
STICs. Thus, it is possible that the fallopian tube is not the tissue of origin in all cases of HGSC, or 
that mechanisms other than STICs can lead to malignant transformation. For example, some HGSCs 
could develop from ovarian cortical cysts [30], although they still might originate from the epithelium 
of the fimbrium, similar to the malignant transformation model of LGSC proposed by Li and 
colleagues, as described above [18]. 
The low accessibility of the fallopian tube by conventional non-invasive methods represents a 
serious limitation to the success of early screening and detection programs for HGSC. Fallopian tubes 
are difficult to visualize via transvaginal ultrasonography (TVUS), and patency tests, either by 
hysterosalpingography or laparoscopy, provide information only about the passage of liquid through, 
but not about putative cellular pathology within the lumen. Thus, new developments in medical 
imaging are necessary to enable programs for early serous cancer detection and prevention. However, 
resolving the role of the fallopian tube in the etiology of ovarian cancer will require prospective 
clinical studies designed to detect malignancy at early stages. A study in Canada focused on  
non-invasive screening of symptomatic women, with a combination of serum determination of the 
tumor marker CA-125 and TVUS [31]. In a group of 1,455 women, a total of 22 gynecological cancers 
were detected, 9 of which were classified as HGSC. Interestingly, 7 of these, which were localized 
outside the ovaries, had a relatively low CA-125 burden and no or very minor abnormalities detectable 
by TVUS on the ovarian surface.  
On the other hand, a number of cell biological questions remains to be resolved in order to elucidate 
the cascade of events in the fallopian tube epithelium which lead to STIC formation. Further 
histological analysis is needed in order to identify precancerous lesions and molecular changes in the 
epithelium that favour malignant transformation. So far, immunohistochemistry for molecular markers 
revealed dysplastic morphological changes in the fallopian epithelium of BRCA1/BRCA2 mutation 
carriers compared to healthy controls, characterized by p53 positive nuclei foci, increased numbers of 
proliferative Ki67 expressing cells and also reduced numbers of p21 and p27 positive cells [32]. The 
observed antibody staining signature was always restricted to secretory cells and did not include 
ciliated cells and is more frequent in patients who develop STICs than in controls. Thus, p53 
“signatures” in fallopian tube epithelium (Figure 2C) are postulated to be a form of cellular atypia  
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in vivo, a benign alteration of secretory cells that provide the basis for malignant transformation and 
development of ovarian cancer. 
4. P53 Inactivation Is a Necessary but not Sufficient Step in the Etiology of HGSC 
Given the prevalence of p53 mutations in HGSC [33], it is clear that signaling pathways regulated 
by this tumor suppressor are of essential importance for the initial stages of cellular alterations which 
eventually lead to transformation. However, there are doubts if p53 signatures have real prognostic 
value when assessing the risk for future cancer development. 
It is known that, p53 activation, marked by its accumulation in the nucleus, belongs to the central 
response to genotoxic stress in healthy cells [34] and p53 signatures are also found in the epithelium of 
healthy women. BRCA-mutated but still healthy women, as well as non-mutated non-neoplastic 
controls, have been shown to have the same frequency of p53 foci in the fimbrial epithelium [35]. Still, 
there was an increase in the number of p53 signatures in tubes containing STICs. Also, mutational 
analysis of DNA retrieved by laser-targeted microdissection of p53 foci showed that the majority of 
them (57%) contained mutated p53 alleles, while all samples from tubes containing STICs were p53 
mutated. It appears that the fimbrial epithelium is susceptible to p53 accumulation but that additional 
genotoxic events and mutations are necessary for malignancy to occur. Interestingly, women with Li 
Fraumeni syndrome do not have increased rates of ovarian cancer. This rare genetic condition, 
inherited in a dominant autosomal fashion, where one copy of the p53 gene is inactivated in the 
germline, dramatically increases the risk for developing a number of malignancies, such as breast 
cancer, brain cancer, leukemia, soft tissue sarcomas etc. Risk is mediated by the relatively high 
probability of a “second hit” and inactivation of the remaining p53 allele due to environmental factors, 
which is sufficient to trigger malignant transformation. Still, loss of p53 function in the fallopian tube 
epithelium alone is not sufficient to cause transformation. Although the examined epithelium of Li 
Fraumeni syndrome mutation carriers contained increased numbers of p53 signatures compared to 
healthy controls, on the same level as HGSC patients’ samples [36], no associated malignancy was 
detected. Thus, it can be concluded that p53 inactivation is a necessary but clearly not sufficient step in 
transformation and additional genetic alternations are needed to trigger development of the disease. In 
the case of BRCA1 germline mutation carriers, this is achieved by additional genomic instability, 
caused through defects in the DNA repair machinery together with the loss of p53 function. 
Consequently, there is a dramatic increase in the risk of developing serous ovarian cancer. Therefore, 
the prevalence of p53 mutations in the tissue samples of HGSC patients do not prove its causality in 
disease etiology, but may rather be a conserved molecular mechanism which is modified in cancer 
cells at some stage of the transformation process, and preserved, due to the competitive advantage it 
confers upon HGSC cells. Since the vast majority of HGSCs are diagnosed at an advanced stage of the 
disease, genotyping of the tumor does not provide any information about when a particular mutation 
occurred. The fact that the fallopian mucosa frequently harbors aberrant p53 phenotypes provides an 
attractive model of the environment prone to conversion to STICs and finally HGSCs, but further 
studies are required before a model of p53 signatures as first precancerous lesion can be accepted as 
definite precursor of serous ovarian cancer. 
  
Int. J. Mol. Sci. 2013, 14 6579 
 
 
5. Modulation of DNA Repair in Carcinogenesis and Mechanisms of Chemoresistance  
Double stranded DNA break repair mechanisms by homologous recombination (HR) represent one 
of the most significant checkpoints for maintaining genome stability. Failure to efficiently correct 
simultaneous disruption of both strands promotes chromosomal rearrangements and thus further 
instability, driving the cell towards uncontrolled growth and transformation [37]. 
However, although deficiencies in homologous recombination mechanisms play a central role in the 
initiation of cellular transformation in HGSC, the progression of the disease at later stages, especially 
the development of resistance to therapy, appears to be dependent on the partial recovery of HR 
function in cancer cells. Elevated HR activity has been shown to promote aneuploidy and chromosome 
rearrangements [38]. Therefore, cancer cells with their robust capacity to overcome DNA breaks have 
a competitive advantage, survive and further diversify in response to therapeutics which mainly work 
as DNA damage inducing agents. In healthy cells, the tumor suppressors p53 and BRCA1/BRCA2 
have a complementary role in maintaining DNA helix integrity (Figure 3A). Upon exposure to 
genotoxic stress, p53 inhibits homologous recombination by binding directly to RAD51 protein and 
also suppressing the expression of the rad51 gene [39]. Also in BCRA1/BRCA2 mutant mouse 
embryos, which are deficient in homologous repair, there is no increase in malignancies, as might be 
expected, but instead a reduced rate of cell proliferation due to the compensatory activation of  
p53 [40], and a subsequent increase in cell cycle arrest through downstream expression of p21 [41]. 
This may explain why patients with the BRCA1/BRCA2-mutant form of HGSC have slightly better 
long-term survival and a longer remission period compared to sporadic cases [42]. This difference is 
thought to arise mainly due to a better response to platinum-based chemotherapy and PARP inhibitors, 
although this needs to be confirmed by additional trials. Indeed the importance of functional HR in 
malignant tissue for long term cancer progression has been demonstrated in a group of 50 patients 
whose HR status was confirmed by RAD51 assay prior to chemotherapy [43]. All patients received 
chemotherapy and PARPi treatment and during the 14 month follow-up, patients deficient in HR had a 
better response and long term prognosis than patients from the HR competent group. In addition 
Norquist and colleagues [44] reported the phenomenon of secondary somatic mutations, restoring the 
protein function, in hereditary BRCA1/BRCA2 patients who exhibit chemoresistance to platinum and 
PARPi. Although the detailed molecular mechanisms of acquired chemoresistance are yet to be fully 
characterized, the dependency of late tumors on functional HR mechanisms is considered to be a 
promising aspect of ovarian tumor biology for the development of new therapeutics.  
6. Fallopian Tube Epithelium in BRCA1/2 Mutation Carriers: Searching for the Molecular 
Fingerprint of Carcinogenesis 
Given the high risk BRCA mutation carries to develop HGSC, as indicated by the appearance of 
STICs, elucidating how the fallopian tube epithelium of carriers differs from controls on a molecular 
and cellular level could give valuable insight into the original cause and mechanism of cellular 
transformation. Indeed, a study of the genome wide expression profile of tubal epithelium in BRCA1 
carriers confirmed that there are significant differences in the expression patterns of analyzed epithelial 
cells compared to controls [45].  
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The fallopian epithelium mucosa is exposed to immense physiological changes, driven by cyclically 
altering hormone levels. This is reflected in major changes of gene expression patterns between 
follicular and luteal phases, irrespective of any BRCA mutation status. However, the epithelium of 
BRCA mutation carriers also has a different signature for genes involved in inflammation signaling 
and DNA damage response compared to the epithelium of unaffected women. The upregulation of 
CEBP-δ, NAMPT, GADD 45-β, and decrease in phospho-STAT3 found in mutation carriers is likely 
to cause altered cellular responses to environmental stimuli, increasing the long term probability of 
cellular transformation. Immunohistochemistry results to complement the microarray findings 
provided the first molecular markers by which BRCA1-affected mucosa can be distinguished from 
healthy tissue. Clearly further studies are needed to elucidate the extent of cellular changes in 
epithelium with a BRCA1 mutation and to identify the core mechanism which is responsible for the 
dramatic susceptibility of these cells to ovarian cancer development. Still, initial findings stress the 
importance of inflammatory signaling, stress response and cell cycle control. Since BRCA mutations 
have only limited penetrance, providing strong risk for future cellular transformation but no direct 
mechanism for imminent cancer development, it is clear that other etiological factors need to be taken 
into account in order to understand the molecular background of HGSC. 
7. The Tumorigenic Effects of Oxidative Stress and Inflammation in the Fallopian Tube 
In addition to the regular epithelial turnover in the genital tract, monthly ovulation is considered to 
be a major event triggering inflammatory signaling at regular intervals in both the ovary and the 
adjacent fallopian fimbriae. Evidence for a tumorigenic effect of ovulation as such comes from several 
different findings. A large prospective epidemiologic study, analyzing over 320,000 women in Europe 
over a decade, confirmed the protective influence of long-term usage of oral contraceptives with regard 
to life-long ovarian cancer risk [46]. Parity, and consequently a prolonged lack of ovulation for a year 
or more, is also known to reduce ovarian cancer risk by 29%, with each new pregnancy further 
reducing the rate by 8%. In contrast, late menopause, associated with ovulation for a longer time 
period is associated with a significantly higher risk for ovarian cancer.  
The influence of ovulation as a cause of increased gonadotropin stimulation as well as oxidative 
stress and local inflammation due to follicle rupture was studied in an in vivo mouse model as well as 
an in vitro 3D baboon model of tubal epithelium. While ovulation-related spikes in FSH and LH 
concentration did not alter the proliferation rate of tubal epithelium, oxidative stress triggered an 
increase in phosphorylated γ-H2AX, a marker of double-stranded DNA breaks in the tubal epithelium. 
Postovulatory tubal epithelium in mice also contained increased numbers of infiltrating macrophages 
close to the site of ovulated oocytes [47]. Nevertheless, while ovulation is a monthly physiological 
event during the reproductive years of most women, the risk of developing ovarian cancer is only 1 in 
72 (SEER program National cancer Institute USA). Clearly, additional genetic and environmental 
factors play a role in the etiology of sporadic ovarian cancer.  
A breakthrough in our understanding of the molecular biology of ovarian cancer may depend on 
gaining a deeper insight into homeostasis, inflammatory signaling and stress responses of normal 
fallopian tube epithelium. Monthly inflammation is not the only source of inflammatory pressure on 
the tubal mucosa. Ascending bacterial infections often cause extensive inflammation and pathology. 
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Although no direct causative relationship between infectious agents and ovarian cancer has been 
conclusively proven as yet, protracted inflammation must be considered as a putative factor 
contributing to carcinogenesis. 
A large population study from Taiwan comparing 67,936 women with a history of pelvic 
inflammatory disease (PID) with 135,872 controls, found a more than two-fold increase in the risk for 
development of ovarian cancer later in life [48]. The risk was directly correlated with the number of 
PID episodes. 
Chlamydia trachomatis (Ctr) is found in up to 25% of patients diagnosed with PID [49] and 57% of 
patients with salpingitis [50], causing inflammation, scarring and occlusion of the fallopian tube. 
Based on the extent and spectrum of molecular interactions that Ctr, an intracellular pathogen, 
establishes within the host cells, it could conceivably trigger long-term cellular changes in the 
epithelial layer of the tube, posing a putative separate risk factor for ovarian cancer. Ctr infection 
triggers extensive epithelial damage, marked by loss of cilia [51,52]. Increased expression of Toll-like 
receptor 2 (TLR2) [53], cytokine secretion and infiltration of T lymphocytes [54] are reported in 
infected tissue. Also, Ctr ex vivo infection causes increased epithelial proliferation and activates the 
Wnt signaling cascade, affecting paracrine regulation of homeostasis [55] .Complementary to this 
finding, numerous in vitro studies of Ctr and Neisseria gonorrhoeae confirm the interference of these 
pathogens with signaling pathways that are known to be altered in HGSC, e.g., PARP signaling [56], 
cell cycle control [57] and apoptosis [58]. However, a causative link between infection and carcinogenesis 
in the genital tract remains difficult to prove, with the limited number of epidemiological studies 
providing contradictory data. 
Ness and colleagues [59] reported a significant difference in IgG antibody titers against Ctr 
elementary bodies and heat shock proteins (CHSP) in the serum of ovarian cancer patients compared to 
the control group, but failed to validate the finding in a larger, population-based group [60]. In a more 
recent patient cohort analyzed by Idahl et al. [61], the presence of IgG anti HSP60-1 antibodies in 
serum was positively associated with the incidence of HGSC. These conflicting findings might be 
partially explained by the often unreliable serology in response to Chlamydia infection. Since Ctr 
infection has a high prevalence in the general population and only a fraction of infections result in 
ascending inflammatory processes, there is a need to identify novel markers which could distinguish 
between uncomplicated lower tract infections and upper tract pathology. Recently Ctr antigens CT157, 
CT423, CT727 and CT396 were identified as markers of upper genital tract infection [62]. Thus, 
further epidemiological studies are necessary to validate these markers for detecting asymptomatic 
chronic salpingitis and explore a potential association between Ctr infection and the development of 
malignancy through gaining a better understanding of the pathogen–host interaction. Alternatively, 
pathogen-specific genetic and/or epigenetic fingerprints remaining after infections might help to trace 
possible etiological links with cancer initiation.  
8. The Molecular Basis for Malignant Transformation in Fallopian Tube Epithelium: Analysis of 
Cellular Pathways  
Realizing the importance of the fallopian tube in the process of carcinogenesis in HGSC, several  
in vitro studies have been designed to simulate the malignant transformation of the fallopian tube 
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epithelial cells by targeting distinct pathways. Jazaeri and colleagues [63] focused on introducing p53, 
BRCA, HRas and Rb mutations, as well as overexpression of c-MYC and hTERT by retroviral 
integration. The two generated cell lines with the highest proliferation capacity in vitro were shown to 
generate tumors in the SCID mouse xenograft model in vivo. Histological analysis of malignant tissue 
revealed great similarities with ovarian cancerous tumors. Interestingly, attempts to reduce the number 
of components in the “oncogenic cocktail”, led to failed tumorigenesis in vivo, demonstrating that 
more profound alterations of the cellular regulatory networks are required to drive cancer formation.  
Recently, Karst and colleagues succeeded in demonstrating the stepwise immortalization and 
subsequent malignant transformation of primary fallopian tube epithelial cells [64]. By introducing 
defined genetic elements and testing combinations of these, they demonstrated successful xenograft 
tumor models when HTERT and SV40 proto-oncogene expression was combined with either cMYC or 
oncogenic Ras. They also found complete in vitro transformation and in vivo tumor growth in the 
absence of the viral oncogene SV40 with a knock-down of p53 in the cells and CDK4 and shPP2A-B56γ 
mutation (the latter being well-known cellular targets of SV40 function). Comparative histological 
analysis of the generated tumors also showed a strong similarity to serous ovarian cancer tissue 
architecture, normally found in patients with extensive peritoneal involvement. Thus, primary fallopian 
tube epithelial cells appear to be a useful in vitro model for studying the development of HGSCs, using 
controlled genetic manipulations and defined experimental settings. Further expansion of similar 
studies to include a more detailed molecular analysis of molecular pathways based on gene candidates 
retrieved from HGSC patient samples, could be of crucial importance for illuminating key phases of 
the transformation process. In recent years, high-throughput technology generated data to make such 
studies comprehensive and feasible. 
In addition to xenograft models for studying HGSC malignant transformation in vivo, there have also 
been attempts to demonstrate the fallopian tube origin of the malignancy in genetically tractable mouse 
models. In a recent study, Kim and colleagues found that combined knockdown of Dicer, an essential 
factor for production of mature miRNAs, together with PTEN, a negative regulator of PI3 kinase and 
therefore activator of Akt signaling, leads to formation of aggressive serous ovarian cancer, with 100% 
lethality between 6 and 13 months after birth [65]. Tumors originated exclusively from the fallopian 
tube, as demonstrated convincingly by histological analysis of early stages of the disease. These findings 
provide an important in vivo “proof of principle” for the fallopian tube model of ovarian carcinogenesis, 
regardless of considerable differences in morphology and physiology between mouse and humans. It also 
brought into focus additional cellular pathways, separate from core components of the DNA stress 
response and repair machinery, which could be essential for development of HGSC. 
9. The Genomic Sequence of Ovarian Carcinoma and Implications for Understanding the 
Etiology of the Cancer Cell 
The concept of the fallopian tube as tissue of origin of HGSC evolved as a hypothesis based on a 
combination of clinical findings in BRCA mutation carriers and histological and molecular similarities 
between healthy fallopian tube mucosa and malignant tissue. A detailed understanding of HGSC 
carcinogenesis and full acceptance of the fallopian tube paradigm, however, will depend on deeper 
insights into the cellular biology of both cancer tissue and fallopian tube. The individual molecular and 
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cellular markers (e.g., PAX8 or p53 mutations) or morphological changes (cellular atypia, STICs) 
presented in detail above, have limited and descriptive value if taken out of context of cell-cell 
communication and regulation of growth and proliferation mechanisms within the tissue. In the last 
decade, research dealing with cancer genomics and cancer stem cells has emerged, which focuses on 
the analysis of signaling pathways, cellular mechanisms, and putative hierarchy in tumor samples, all 
of which should help to resolve the remaining questions about the origin of HGSC and offer new 
therapeutic strategies. Although many of the approaches dealing with cancer stem cells, epithelial 
mesenchymal transition and tumour dissemination are yet to find their way into clinical practice, they 
provide a valuable basis that should yield a therapeutic breakthrough in the future.  
Despite the great heterogeneity in HGSC tissue samples, modern genomics has enabled large-scale 
analysis of the genetic changes behind the malignant phenotype, and discovery of common molecular 
patterns. In 2011, the Cancer Genome Atlas (TCGA) consortium completed a comprehensive genomic 
analysis of 489 serous ovarian carcinoma samples. This large scale project included DNA sequencing, 
gene copy number analysis, mRNA and miRNA profiling and determination of methylation changes. 
Parallel, complementary pipelines not only allowed the significance of known molecular markers to be 
tested, but also led to the identification of so far unknown players and altered cellular mechanisms. 
The results confirmed that inactivation of the p53 tumor repressor pathway represents a central 
component of nearly all analyzed tumors (96%) and a converging point of cellular changes which 
eventually lead to advanced tumor progression. Mutations of nine other genes occurred with lower but 
significant frequency, many of which were already linked to HGSC in previous studies, including 
BRCA1 and BRCA2, NF1, CDK12 and RB1 [66,67]. 
However, perhaps the most valuable new insight brought by TCGA analysis was an understanding of 
the complexity of regulation on a genomic level (Figure 3B). Only a minor fraction of alterations in 
cancer cells is due to classical mutations, e.g., changes in protein coding regions. Instead, the 
combination of structural genomic alterations, e.g., changes in copy number, and alterations in regulatory 
mechanism e.g., expression pattern and epigenetic modulation of gene activity, play a crucial role in 
cellular transformation. For example, the TCGA study confirmed a recurring pattern of a total of 8 gains 
and 22 losses within chromosomal bands many of which have been reported previously [68,69]. 
Downstream analysis of affected genes identified CMYC, CCNE1, MECOM, ID4, PAX8 and TERT 
as focal amplification peaks. Genomic regions encoding the well-known tumor suppressor genes 
PTEN, RB1 and NF1 were found to be frequently deleted in HGSC [70]. Integrated data from different 
experimental set ups (sequencing, methylation analysis, copy number and gene expression profiles) 
were pooled and subjected to network analysis revealing which biological pathways are altered in 
ovarian cancer tissue. DNA repair mechanisms as well as RB1, PI3K and NOTCH pathways were 
significantly modified in many ovarian cancer tissues. Moreover, the regulatory network of the 
transcription factor FOXM1, known for its role as an oncogene in basal cell carcinoma, glioblastoma, 
breast cancer and prostate cancer [71,72], was for the first time associated with ovarian cancer. In 87% 
of all HGSC cases, the FOXM1 signaling was altered, in congruence with the identified overexpression 
of the downstream target genes AurB, CCNB1, PLK1, CDC25 and BIRC5. In a more detailed follow-up 
study, in vitro models based on the ovarian cancer cell line OVCA433 showed a clear dependency of 
FOXM1 on upstream activation of MEK/ERK signaling, [73]. More data will be needed to elucidate 
the involvement of FOXM1 in serous ovarian cancer development and progression, but these findings 
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are potentially important with regard to therapeutic strategies, since potent inhibitors of FOXM1 exist, 
which are known to have tumor suppressing capacity in other malignancies [74]. 
Figure 3. P53 and BRCA regulation of DNA repair represents a central component of 
altered cellular function in serous ovarian cancer. (A) BRCA proteins are activated in 
response to genotoxic stress via the ATM/ATR pathway and required for homologous 
recombination, while p53 protects cells from defective BRCA1 function by triggering cell 
cycle arrest and apoptosis. A combination of p53 and BRCA mutations, seen frequently in 
BRCA mutation carriers, thus allows several mechanisms to drive cell fate towards malignant 
transformation, e.g., myc overexpression or akt kinase signaling; (B) The most prominent 
genomic changes found in serous ovarian cancer patients ( The Cancer Genome Atlas TCGA 
study [19]). Their function was altered by different genetic molecular mechanism: somatic 
mutations, changes in copy number and expression level by methylation. 
 
10. Regulation of Epithelial-Mesenchymal (EMT) Transition and Dissemination of HGSC 
Aggressive spread of cancer tissue is another hallmark of HGSC which make it difficult to treat. 
Therefore, it is of pivotal interest to elucidate the cellular mechanisms that drive tumor growth as 
diseases progresses. A better understanding of fallopian tube epithelial homeostasis may be necessary 
to achieve this. 
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The majority of epithelial cancers undergo epithelial-mesenchymal transition (EMT) at some stage 
of disease progression. This is a core mechanism in tumorigenesis of epithelial tissues that leads to 
invasiveness and aggressive proliferation of cells. Loss of adhesion and polarity is mediated by 
suppression of E-cadherin expression and disassembly of adherens junctions. It has been shown that 
the ovarian cancer cell lines SKOV3 and OVCAR5 in response to stimulation by EGF exhibit a strong 
downregulation of E cadherin and increased invasion capability. Mechanism is dependent on induction 
of transcription factors Egr1 and Snail [75]. Many studies independently found a correlation between 
the EMT process and development of chemo resistant properties of the cancer. Direct contribution of 
transcriptional factors Snail and Slug in cisplatin resistance was found by Haslehurst and colleagues [76] 
in proteomic and transcriptional analysis of ovarian cancer cell lines and confirmed in a cohort study 
of clinical samples. 
Also, induction of the EMT-related transcription factors snail and slug occurs downstream of other 
receptors, for example the endothelin A Receptor (EtAR), which is upregulated in primary tumors of 
patients resistant to platinum based therapy plus paclitaxel. Blockage of EtAR with zibotentan strongly 
reduced EMT and proliferation of EOC cell lines in vitro and tumor growth in a xenograft model  
in vivo, and resensitized cells to chemotherapy [77]. These are only a few examples where extracellular 
signaling pathways are shown to influence EMT transition in ovarian cancer. Ultimately, however, 
conversion of the cellular phenotype from epithelial to mesenchymal is an intracellular mechanism that 
is the end result of interfering developmental programs and environmental signals.  
Maintenance of epithelial phenotype with strong Cdh1 expression is a property of differentiated and 
polarized cells. Events which change the intracellular environment towards a less differentiated status 
and pluripotency can also contribute to EMT. Thus, the stem cell marker nanog was found expressed 
in ovarian cancer cell lines and patients with advanced tumor stages, resistant to chemotherapy [78] 
Further, nanog was found to be an independent prognostic factor for disease survival of patients, 
increasing invasiveness and metastatic potential by direct suppression of Cdh1, caveolin-1, FOXO1, 
FOXO3a, FOXJ1 and FOXB1 [79]. 
Different scenarios could be envisaged which could initiate reprogramming of cells towards 
stemness during tumorigenesis. So far, it has been shown that nanog expression directly depends on 
p53 levels in the cell, which on its own is affected by expression of microRNA-214 [80]. This is only 
one example of the interconnectivity of cellular pathways, in this case linking DNA repair with cell 
fate determinants and EMT mechanisms. When applied to the situation within the premalignant 
epithelial layer, the loss of p53 frequently seen in tubal fimbriae should lead to ectopic expression of 
nanog in differentiated epithelial cells, potentially reversing their lineage commitment and life  
span. This and other similar observations from cancer cells are yet to be tested in non-malignant,  
pre-cancerous tubal epithelium in order to establish a clear causal relationship and determine their 
importance for the initial transformation process. 
11. Notch Paracrine Signaling, Stemness, and Tumor Progression 
Proliferation, regeneration and renewal in epithelium are regulated by complex mechanisms of  
cell-cell communication and paracrine signaling. During the last decade, in numerous different tissues 
(stomach, intestine, colon, skin, nervous system etc.), adult stem cells have been identified [81–83] 
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which enable long term sustained renewal and generation of healthy, differentiated cells. They reside 
within a niche in close communication with the surrounding mucosa, and give rise to progeny which 
initiate the differentiation process, undergoing further divisions along the way. This cell fate determination 
process within the tissue is tightly regulated by a paracrine signaling network and integration of Wnt, 
Notch, BMP and Shh signaling cascades. Mechanisms of epithelial renewal of the fallopian tube remain 
obscure, as some evidence also points to the existence of pluripotency in the epithelial layer [84]. 
So far it is unclear if there is a relationship between healthy tissue stem cells and cancer stem  
cells which have been described in numerous malignancies. Cancer stem cells could originate from 
tissue-specific stem cells which have acquired further mutations and the capability to growth outside 
the niche independent of regulatory mechanisms. Alternatively, cancer stem cells could be the result of 
reprogramming and de-differentiation of normal somatic cells during transformation.  
Recent data from both clinical studies and in vitro analysis of cell lines shows the importance of the 
NOTCH signaling pathway for the progression of HGSC and general survival of the patients. 
Increased expression levels of NOTCH3 correspond with significantly higher recurrence rates of 
cancer in affected patients and a shorter disease-free periods [85]. Overexpression of NOTCH3 leads 
to increased platinum resistance, whereas γ-secretase treatment, which inhibits intracellular 
transmission of the notch signal, restores sensitivity to therapy and depletes cancer stem cells in the 
tumor [86]. It remains to be seen if the effects of NOTCH3 inhibition can be attributed to the specific 
suppression of cancer stem cells within the tumor population. Also, more research is needed into the 
general mechanisms of notch paracrine signaling in the fallopian tube and the ovary, in order to 
establish its contribution to carcinogenesis in more detail.  
12. Cancer Stem Cells in Proliferation and Survival of HGSC 
Although EOCs appear to be of clonal origin, during the advancement of the tumor and its 
spreading not all cells have the same potential to initiate and sustain growth. It is evident that only a 
minor percentage of cells retrieved from malignant tissue ex vivo, shows clonogenic growth in vitro 
and can give rise to novel tumors in xenograft models in vivo. Cancer stem cells (CSCs) were first 
described in hematopoietic cancers, as a subpopulation of cells that is long-lived with self renewal 
capacity, differentiation potential and resistance to therapy. In ovarian cancer, CD44+CD117+ cells 
were identified as a subpopulation of cells from the primary tumor, with sustained capacity to initiate 
tumorigenesis in xenografts, in contrast to CD44-CD117- cells [87]. CD44+MyD+ positive cells 
isolated from patients also showed properties of CSCs in vitro and in vivo [88]. The number of CD44+ 
cells in the tumor corresponds with the stage of the disease, as the percentage of positive cells in 
histological samples rises from 6.3% in primary tumors to 18% in metastatic tissue in representative 
patients. The differential expression profile of CD44+ versus CD44- EOC cells revealed a strong 
upregulation of cytokeratin 18, β-catenin, and entire gene families involved in regulation of cell cycle 
and apoptosis. CSCs were found to exhibit functional, constitutively active NfkB signaling, probably 
mediated by the upstream TLR/MyD 88 pathway. As a consequence of these changes, cells develop 
resistance to the standard therapeutic drugs paclitaxel and carboplatin. Additional studies reported 
stemness potential in cells positive for CD133, aldehyde dehydrogenase isoform 1 (ALDH1), CD24+ 
and EpCAM+ [89,90] (Figure 4A).  
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Figure 4. Ovarian cancer stem cells (CSC) are responsible for disease progression and 
acquisition of chemoresistance. (A) Candidate proteins identified as ovarian CSC markers; 
(B) Model of CSC-driven cancer progression: CSCs represent a small population of the 
initial primary tumor, which are resistant to chemotherapy. Following treatment, they give 
rise to more differentiated cells, which are then also resistant to therapeutics in the recurrent 
phase of the disease; (C) The tumor microenvironment, comprised of different cell types, 
influences the cancer tissue directly affecting the behavior of CSCs and tumor growth patterns. 
 
The diversity of reported markers for ovarian cancer stem cells may be indicative of different 
origins of the cancer initiating cells. Alternatively, certain discrepancies in reported markers might be 
due to methodological differences in the design of the studies analyzing established ovarian cancer cell 
lines versus primary fresh material, selection criteria of patient samples etc. For example, it has 
recently been demonstrated that in vitro cultivation of fresh cells isolated from primary tumors in the 
presence of fetal calf serum leads to a gradual loss of the stem cell markers CD133, ALDH1, CD24, 
CD44 and CD117 [91]. Transplantation into the SCID mouse model led to recovery of CD133, and 
ALDH1 while other markers were permanently lost. However, a common factor in all of the studies 
dealing with presumptive cancer stem cells isolated from HGSC is their intrinsic capacity to drive 
tumor growth and disease progression via multiple mechanisms simultaneously. The importance of 
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inflammatory signaling for the function of CSCs was demonstrated by Long et al. [92] who defined 
EOC stem cells as CD133+, expressing receptors for the chemokine signaling components CCL5 and 
receptors CCR1, CCR3 and CCR5. They showed that an autocrine chemokine signaling loop 
perpetuates the NFkB signaling cascade and increases the release of MMP9, which mediates 
invasiveness. This represents one potential mechanism by which cancer stem cells gain a competitive 
advantage over other cells from the tumor. For example expression of the endothelin-A receptor, 
mentioned previously for its role in chemoresistance and EMT induction, is essential for both ICAM1 
upregulation, which ensures immune cell recruitment, and for proliferation of the chemoresistant 
CD133+ CSC population [93]. Thus CSCs appear to play an important role in all crucial steps of 
pathology development and disease spread, from modulation of the immune response, to angiogenesis, 
invasiveness and dissemination. In addition, their resistance to standard chemotherapeutical agents 
imposes great limitations on treatment options (Figure 4B). One of the great difficulties in translating 
emerging knowledge about ovarian cancer stem cells into efficient therapeutic strategies is our lack of 
fundamental understanding of their origin in healthy tissue and the regulatory mechanisms which 
control their niche in the tumor. For example, accounted differences in isolated CSC populations could 
be explained by different stages of stemness and differentiation. Further, numerous studies have 
reported a contribution of the individual components of the tumor microenvironment to the 
proliferation and survival of CSCs in selected patients. The malignant potential of the tumor is driven 
by epithelial cells, but mesenchymal and endothelial cells of the stroma are also known to play an 
important role in creating favorable conditions for the tumor to spread [94,95]. However, it remains 
unclear, whether and to what extent non-epithelial cells influence the regulation of stemness and 
differentiation mechanism (Figure 4C), a topic which is currently an intensive focus of research. 
Defined niches of adult stem cells in the epithelial layer of the intestinal tract exhibit autonomous 
developmental and regulatory programs which are independent of the underlying parenchyma. 
Therefore, they can exert the complete repertoire of stem cell functions (long term propagation and 
differentiation) in vitro without the presence of non-epithelial cells [96]. It is possible, however, that 
CSCs evolved interaction strategies with their environment which provide them with an additional 
selective advantage and ensure unlimited growth. 
13. Conclusions  
The identification of fallopian tube epithelium as the tissue of origin of HGSC provides a basis for 
critical evaluation of the molecular mechanisms of pathology behind this deadly disease. In the present 
paper we have summarized both clinical and biological findings that point to the central role of the 
fallopian tube epithelial cells in the carcinogenesis of HGSC. Even though many important questions 
remain to be answered, including the exact mechanism of migration of the transformed fallopian cells 
to the ovary, embryological and genetic profiling shows clear evidence of the tight association between 
Fallopian tube and HGSC. Moreover, future studies are warranted to illuminate the initial cause of 
malignant transformation and the course of events which lead to the appearance of p53 mutation in 
tubal fimbriae, and hence the development of STICs. The regulatory mechanisms of epithelial renewal 
in the healthy tube should also be investigated, especially the existence of plasticity and pluripotent 
cells which could potentially lead to identification of the cancer initiating cells.  
Int. J. Mol. Sci. 2013, 14 6589 
 
 
The elucidation of the pathways of carcinogenesis will have an immediate implication in the clinical 
management of BRCA mutation carriers, in terms of prophylactic salpingectomy with preservation of 
the hormonally active ovarian tissue. Of course, prior to implementation of this strategy as the standard 
of care in clinical practice, any remaining uncertainties about the origin of HGSC must be clarified. 
Multiple lines of evidence indicate that the epithelium of the fallopian tube constitutes an ideal model 
for studying the inflammatory and potentially infection-related basis of HGSC and also offer a 
platform for innovative screening assays of gene function profiling, as well as for testing the effects of 
new therapeutic compounds on cell transformation and growth. In particular, the biology of ovarian 
CSCs and mechanisms of chemoresistance acquisition are highly promising areas of research, which 
may provide new insights that could lead to a therapeutic and prognostic breakthrough of this  
fatal disease. 
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